National Bank of Canada
TERN

National Bank of Canada’s Terns Pharmaceuticals TERN Stock Holding History

National Bank of Canada’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-100
Closed -$679 – 3036
2024
Q2 		$679 Hold
100
– – ﹤0.01% 2538
2024
Q1 		$555 Buy
+100
New +$653 ﹤0.01% 2591

Other funds holding TERN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

National Bank of Canada's TERN Position: Q3 2024 in Review

National Bank of Canada sold out of Terns Pharmaceuticals (TERN) in Q3 2024, closing a stake of 100 shares — an estimated $679 sold.

National Bank of Canada first reported a position in TERN in Q1 2024 and held it in 2 quarters. The position peaked at $679 in Q2 2024. 156 funds tracked by Wall St. Rank hold TERN as of Q3 2024.

  • National Bank of Canada reported no remaining Terns Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • National Bank of Canada sold 100 Terns Pharmaceuticals shares in Q3 2024, an estimated $679.
  • National Bank of Canada first reported a position in Terns Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • National Bank of Canada's Terns Pharmaceuticals position peaked at $679 in Q2 2024.
  • 156 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q3 2024.

Based on National Bank of Canada's 13F filing for Q3 2024, filed 12 Nov 2024.